Compare Inovio Pharmaceuticals Inc (INO) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs QUALCOMM, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while QUALCOMM, Inc. trades at $175.5 (market cap $187.95B). The key difference: QUALCOMM, Inc. is far larger — about 1675.3× Inovio Pharmaceuticals Inc's market cap, and QUALCOMM, Inc. pays a 2.09% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and QUALCOMM, Inc. for 87 Days on average.
| INO | QCOM | |
|---|---|---|
Market Cap | $112.19M | $187.95B |
Volume | 3,201,278 | 9,535,042 |
Sector | Health | Technology |
52-Week High | $2.60 | $251.10 |
52-Week Low | $0.66 | $124.07 |
Typical Hold Time | 43 Days | 87 Days |
Enterprise Value | $83.51M | $194.92B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
Qualcomm (QCOM) trades at $176.01, down 0.59% on the day, with a bearish technical signal and key support at $173. The company reported mixed Q2 2026 earnings, missing EPS estimates, but maintains strong profitability with a 21.01% net margin and 33.75% ROE. Recent news highlights a transformative $60 billion AI partnership with Amazon, boosting sentiment despite near-term volatility.
QCOM presents a compelling risk-reward profile with a consensus price target of $204.48, implying 16% upside. Strengths include robust cash flow and diversification into AI/data centers, but risks involve execution on new initiatives and dependence on smartphone markets. Analyst consensus leans Hold, reflecting cautious optimism amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
